Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Existing Cancer Treatment Could be Used for Common

publication date: Jul 13, 2018
 | 
author/source: University of Glasgow

University of GlasgowA cancer treatment already approved for use in certain types of cancer has been found to block cell growth in a common form of lung cancer for which there is currently no specific treatment available.

The new findings, published today in Science Translational Medicine and led by the University of Glasgow, suggest that a large number of patients could benefit from this treatment – a second generation EGFR inhibitor (a drug that slows down or stops cell growth) – if used in combination with additional therapies.
 
The scientists hope the treatment could be deployed for use in patients in the near future, given it is already approved for the treatment of other cancers.
 
Cancers of the lung kill more people worldwide than cancers of any other organ, more than 1.5m people per annum. The largest subtype of lung cancer, which the researchers studied, is adenocarcinoma.
 
One third of adenocarcinoma cancers carry a mutant gene called KRAS, which the researchers show requires the activity of any of four ‘EGFR/ERBB growth factor receptors’ to drive cell proliferation. There are presently no KRAS-inhibiting drugs available for treatment of these cancers and first generation EGFR drugs have failed to show any benefit to this form of cancer.
 
However, the scientists in this study found that, unlike first-generation EGFR inhibitors, one particular second-generation EGFR inhibitor – a multi-ERBB inhibitor - blocked the proliferation of KRAS-mutant lung cancer cells in lab studies and actually prevented the formation of KRAS-driven lung cancers in mice.
 
Lead author Dr Daniel Murphy, Senior Lecturer at the University’s Institute of Cancer Sciences and a scientist at Glasgow’s Cancer Research UK Beatson Institute, said: “There is a pressing need to develop alternative strategies for more effective treatment of KRAS?driven lung cancer, and this is a promising breakthrough which we hope could benefit patients soon.
 
“The inhibitor we studied – a multi-ERBB inhibitor – helped sensitise tumours and was of therapeutic benefit when used in combination with another cancer drug called Trametinib, resulting in a clear extension of lifespan.
 
“Based on our findings, we hope lung cancer patients with the KRAS-driven form of lung cancer may in future benefit from inclusion of this inhibitor in their treatment plan.”
 
Unwanted side-effects of these drugs on normal tissues remains a concern, however, new strategies to limit delivery of these drugs to the tumour site could reduce such side-effects and greatly improve the utility of this class of therapeutics.
 
The paper, ‘The ERBB network facilitates KRAS-driven lung tumorigenesis,’ is published in Science Translational Medicine. The work was funded by a MINT
Collaborative grant from Merck Sharpe & Dohme; a Deutsche Krebshilfe grant; and grants from the European Commission Marie Curie Actions and the British Lung Foundation in collaboration with the Scottish Government Chief Scientist Office.




 

News Channels

 

 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 

 

 

 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events